Page 2 - Timothys Ernst News Today

Grantham Mayo Van Otterloo & Co. LLC decreased its holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO – Free Report) by 2.7% in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 65,400 shares of the medical research company’s stock after selling 1,800 shares during the quarter. Grantham […]

Bio-Rad Laboratories, Inc. (NYSE:BIO – Get Free Report) EVP Timothy S. Ernst sold 300 shares of the firm’s stock in a transaction on Wednesday, August 23rd. The stock was sold at an average price of $384.69, for a total value of $115,407.00. Following the completion of the transaction, the executive vice president now owns 2,416 […]

Picton Mahoney Asset Management bought a new stake in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO – Get Rating) in the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund bought 354 shares of the medical research company’s stock, valued at approximately $149,000. A number of other hedge funds and […]

Bio-Rad Laboratories, Inc. (NYSE:BIO – Get Rating) shares saw unusually-strong trading volume on Thursday . Approximately 127,056 shares traded hands during mid-day trading, a decline of 31% from the previous session’s volume of 182,982 shares.The stock last traded at $374.94 and had previously closed at $373.35. Analyst Ratings Changes A number of equities analysts have […]

Levin Capital Strategies L.P. purchased a new position in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO – Get Rating) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 847 shares of the medical research company’s stock, valued at approximately $356,000. Several other hedge funds have also […]

Thompson Siegel & Walmsley LLC grew its position in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO – Get Rating) by 960.5% during the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 201,222 shares of the medical research company’s stock after purchasing an additional 182,248 shares during the […]

StockNews.com started coverage on shares of Bio-Rad Laboratories (NYSE:BIO – Get Rating) in a report released on Thursday. The brokerage issued a buy rating on the medical research company’s stock. Other equities analysts have also issued reports about the stock. Royal Bank of Canada raised their target price on shares of Bio-Rad Laboratories from $571.00 […]

Bio-Rad Laboratories, Inc. (NYSE:BIO – Get Rating) shares saw unusually-high trading volume on Monday . Approximately 64,548 shares changed hands during mid-day trading, a decline of 64% from the previous session’s volume of 177,345 shares.The stock last traded at $383.72 and had previously closed at $382.14. Analysts Set New Price Targets BIO has been the […]

Bio-Rad Laboratories, Inc. (NYSE:BIO – Get Rating) was the recipient of a large decline in short interest during the month of April. As of April 30th, there was short interest totalling 236,400 shares, a decline of 13.8% from the April 15th total of 274,400 shares. Currently, 1.1% of the company’s shares are sold short. Based […]

WASHINGTON TRUST Co lifted its stake in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO – Get Rating) by 62.5% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 78 shares of the medical research company’s stock after purchasing an additional 30 shares during […]